Compare Mesoblast Limited (MESO) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Xylem, Inc. — how do they compare? Mesoblast Limited trades at $15.13 (market cap $1.90B), while Xylem, Inc. trades at $107.56 (market cap $25.11B). The key difference: Xylem, Inc. is far larger — about 13.2× Mesoblast Limited's market cap, and Xylem, Inc. pays a 1.6% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 12 Days and Xylem, Inc. for 51 Days on average.
| MESO | XYL | |
|---|---|---|
Market Cap | $1.90B | $25.11B |
Volume | 143,591 | 4,385,511 |
Sector | Health | Industrials |
52-Week High | $20.96 | $152.95 |
52-Week Low | $13.19 | $105.69 |
Typical Hold Time | 12 Days | 51 Days |
Enterprise Value | $1.98B | $26.89B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $15.13, up 5.0% in the last 24 hours, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $102.14 million in 2025, though revenue grew substantially to $120 million in 2026. Recent milestones include completing a Phase 3 trial for chronic back pain treatment and achieving $115 million in RYONCIL net revenue for the full year 2026, indicating a transition to a commercial-stage company.
The outlook is mixed; strong revenue growth and pipeline progress offer upside potential, but persistent losses and high cash burn pose significant risks. Analyst sentiment is cautiously optimistic with a 45% buy rating, yet the stock faces execution and regulatory hurdles in bringing new therapies to market.
Xylem (XYL) trades at $107.56, up 0.27% today, with a bearish technical signal but strong fundamentals. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $1.46 exceeding the $1.35 estimate. The company announced acquisitions of Cornell Pump and Roper Pump to bolster industrial growth, alongside a new CFO appointment effective September 2026.
Outlook is positive due to robust revenue growth, margin expansion, and strategic acquisitions, though near-term technical weakness and competitive pressures pose risks. Analyst consensus price target of $152.38 implies significant upside, supported by a 47.5% buy rating among coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
